TY - JOUR
T1 - Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
AU - Shinjo, Samuel Katsuyuki
AU - Kim, Minchul
AU - Hoff, Leonardo Santos
AU - Missé, Rafael Giovani
AU - Sen, Parikshit
AU - Naveen, R.
AU - Day, Jessica
AU - Cordeiro, Rafael Alves
AU - Júnior, Jucier Gonçalves
AU - Chatterjee, Tulika
AU - Lilleker, James B.
AU - Agarwal, Vishwesh
AU - Kardes, Sinan
AU - Milchert, Marcin
AU - Gheita, Tamer
AU - Salim, Babur
AU - Velikova, Tsvetelina
AU - Gracia‐ramos, Abraham Edgar
AU - Parodis, Ioannis
AU - O'callaghan, Albert Selva
AU - Nikiphorou, Elena
AU - Makol, Ashima
AU - Tan, Ai Lyn
AU - Cavagna, Lorenzo
AU - Saavedra, Miguel A.
AU - Ziade, Nelly
AU - Knitza, Johannes
AU - Kuwana, Masataka
AU - Nune, Arvind
AU - Distler, Oliver
AU - Chinoy, Hector
AU - Agarwal, Vikas
AU - Aggarwal, Rohit
AU - Gupta, Latika
N1 - Funding Information:
HC is supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.
Funding Information:
Increasing recognition of the importance of pain in AIRDs and its negative effect on HRQoL has galvanized efforts to develop tools to reliably assess these symptoms and advance knowledge in the field. The Patient‐Reported Outcomes Measurement Information System (PROMIS) set measures, funded by the National Institutes of Health (NIH), provides accurate and valid item banks related to various health domains, calibrated by the item response theory. This flexible and reliable instrument can be used to capture the domains of physical and mental health and social well‐being in a variety of conditions, facilitating patient status monitoring and the decision‐making process. 9 9‐11
Funding Information:
The authors thank all members of the COVAD study group for their invaluable role in the collection of data. The authors thank all respondents for filling the questionnaire. The authors thank The Myositis Association, Myositis India, Myositis Support and Understanding, Myositis UK, the Myositis Global Network, Cure JM, Cure IBM, Sjögren's India Foundation, EULAR PARE, and various other patient support groups and organizations for their invaluable contribution in the dissemination of this survey among patients which made the data collection possible. The authors also thank all members of the COVAD study group.
Publisher Copyright:
© 2023 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
PY - 2023/4
Y1 - 2023/4
N2 - Abstract Objectives To compare pain intensity among individuals with idiopathic inflammatory myopathies (IIMs), other systemic autoimmune rheumatic diseases (AIRDs), and without rheumatic disease (wAIDs). Methods Data were collected from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an international cross-sectional online survey, from December 2020 to August 2021. Pain experienced in the preceding week was assessed using numeral rating scale (NRS). We performed a negative binomial regression analysis to assess pain in IIMs subtypes and whether demographics, disease activity, general health status, and physical function had an impact on pain scores. Results Of 6988 participants included, 15.1% had IIMs, 27.9% had other AIRDs, and 57.0% were wAIDs. The median pain NRS in patients with IIMs, other AIRDs, and wAIDs were 2.0 (interquartile range [IQR] = 1.0?5.0), 3.0 (IQR = 1.0?6.0), and 1.0 (IQR = 0?2.0), respectively (P
AB - Abstract Objectives To compare pain intensity among individuals with idiopathic inflammatory myopathies (IIMs), other systemic autoimmune rheumatic diseases (AIRDs), and without rheumatic disease (wAIDs). Methods Data were collected from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an international cross-sectional online survey, from December 2020 to August 2021. Pain experienced in the preceding week was assessed using numeral rating scale (NRS). We performed a negative binomial regression analysis to assess pain in IIMs subtypes and whether demographics, disease activity, general health status, and physical function had an impact on pain scores. Results Of 6988 participants included, 15.1% had IIMs, 27.9% had other AIRDs, and 57.0% were wAIDs. The median pain NRS in patients with IIMs, other AIRDs, and wAIDs were 2.0 (interquartile range [IQR] = 1.0?5.0), 3.0 (IQR = 1.0?6.0), and 1.0 (IQR = 0?2.0), respectively (P
KW - autoimmune diseases
KW - functional status
KW - myositis
KW - pain
KW - rheumatic diseases
UR - http://www.scopus.com/inward/record.url?scp=85150491061&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/78900c6e-2d19-376d-9da6-305a63230254/
U2 - 10.1111/1756-185X.14636
DO - 10.1111/1756-185X.14636
M3 - Article
SN - 1756-1841
VL - 26
SP - 727
EP - 739
JO - International Journal of Rheumatic Diseases
JF - International Journal of Rheumatic Diseases
IS - 4
ER -